SCHEMBL3637356

SCHEMBL3637356

CC(Nc1nc2ccc(Oc3ccc([N+](=O)[O-])nc3)cc2s1)C1(I)CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.38
SCD O00767 1/20 0.37
RAB9A P51151 5/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 4/20 0.36
POLB P06746 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
ATAD2 Q6PL18 1/20 0.36
MAPT P10636 5/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
PKM P14618 1/20 0.35
CSF1R P07333 4/20 0.34
PDGFRB P09619 1/20 0.34
KIT P10721 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848854 0.82 RAB9A (0.43) PTPN1SCDRAB9AMEN1KMT2A
SCHEMBL2848851 0.82 RAB9A (0.43) PTPN1SCDRAB9AMEN1KMT2A
SCHEMBL3635740 0.80 ATAD2 (0.52) SCDRAB9AMEN1KMT2ANPC1
SCHEMBL2840566 0.75 NPC1 (0.42) PTPN1RAB9AMEN1KMT2ANPC1
SCHEMBL3637760 0.73 RIPK1 (0.42) PTPN1SCDRAB9ANPC1MAPT
SCHEMBL2842304 0.67 NPC1 (0.44) RAB9ANPC1ATAD2MAPTPKM
SCHEMBL2842309 0.67 NPC1 (0.44) RAB9ANPC1ATAD2MAPTPKM
SCHEMBL2851202 0.67 CSF1R (0.47) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL2851204 0.67 CSF1R (0.47) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL2850067 0.66 USP30 (0.48) RAB9ANPC1MAPTPKMCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE Novartis Ag (CH) 2010-02-17 EP disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed